Related references
Note: Only part of the references are listed.OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study
Claudia Altamura et al.
JOURNAL OF NEUROLOGY (2023)
FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine
Lars Jacob Stovner et al.
CEPHALALGIA (2022)
NGF Enhances CGRP Release Evoked by Capsaicin from Rat Trigeminal Neurons: Differential Inhibition by SNAP-25-Cleaving Proteases
Mariia Belinskaia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
The chronicle of headache treatment throughout human history from trepanation to perisutural botulinum toxin injections
Murat Kara et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2022)
The trigeminal pathways
Louis-Marie Terrier et al.
JOURNAL OF NEUROLOGY (2022)
Dural Immune Cells, CGRP, and Migraine
Louis K. Balcziak et al.
FRONTIERS IN NEUROLOGY (2022)
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
Maria Dux et al.
CELLS (2022)
The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine
Simona Guerzoni et al.
NEUROLOGICAL SCIENCES (2022)
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
Raffaele Ornello et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
Antidromic Spike Propagation and Dissimilar Expression of P2X, 5-HT, and TRPV1 Channels in Peripheral vs. Central Sensory Axons in Meninges
Oleg Gafurov et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2021)
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
Raffaele Ornello et al.
PAIN AND THERAPY (2021)
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
Baraldi Carlo et al.
FRONTIERS IN NEUROLOGY (2021)
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Raffaele Ornello et al.
PAIN AND THERAPY (2021)
Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators
Karl Messlinger et al.
JOURNAL OF NEURAL TRANSMISSION (2020)
Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy
Antonio Santoro et al.
NEUROLOGICAL SCIENCES (2020)
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
Eleonora De Matteis et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
Rami Burstein et al.
HEADACHE (2020)
The fifth cranial nerve in headaches
J. C. A. Edvinsson et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries
Ruth Ruscheweyh et al.
HEADACHE (2020)
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
Andrew M. Blumenfeld et al.
JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH (2020)
Current understanding of meningeal and cerebral vascular function underlying migraine headache
Dan Levy et al.
CEPHALALGIA (2019)
Cortical spreading depression as a site of origin for migraine: Role of CGRP
Liesl N. Close et al.
CEPHALALGIA (2019)
Current understanding of trigeminal ganglion structure and function in headache
Karl Messlinger et al.
CEPHALALGIA (2019)
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
William B. Young et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study
William B. Young et al.
JOURNAL OF HEADACHE AND PAIN (2019)
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
Fayyaz Ahmed et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data
David W. Dodick et al.
CEPHALALGIA (2019)
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
Paul K. Winner et al.
DRUG SAFETY (2019)
CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura
Aaron J. Schain et al.
JOURNAL OF NEUROSCIENCE (2019)
Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain
Meredith Barad et al.
REGIONAL ANESTHESIA AND PAIN MEDICINE (2019)
Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA
A. Alpuente et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study
Catherine Stark et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Ultrasound-Guided Perisutural Botulinum Toxin Injection for Chronic Migraine Headache Initial Report With Technical Description
Murat Kara et al.
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION (2019)
Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats
Agustin Melo-Carrillo et al.
CEPHALALGIA (2019)
OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine
Alina Masters-Israilov et al.
HEADACHE (2019)
Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience
Fabrizio Vernieri et al.
HEADACHE (2019)
Prognosis Following Discontinuation of OnabotulinumA Therapy in Super-responding Chronic Migraine Patients
Jason Ching et al.
HEADACHE (2019)
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
John F. Rothrock et al.
HEADACHE (2019)
Current and emerging evidence-based treatment options in chronic migraine: a narrative review
Elio Clemente Agostoni et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Mechanisms of Botulinum Toxin Type A Action on Pain
Ivica Matak et al.
TOXINS (2019)
C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system
Jacob C. A. Edvinsson et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Migraine Epidemiology, Burden, and Comorbidity
Rebecca C. Burch et al.
NEUROLOGIC CLINICS (2019)
Botulinum toxin injections to cranial sutures for chronic migraine Rewinding the technique using ultrasound imaging
Murat Kara et al.
TOXICON (2019)
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
Andrew M. Blumenfeld et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Non-Trigeminal Nociceptive Innervation of the Posterior Dura: Implications to Occipital Headache
Rodrigo Noseda et al.
JOURNAL OF NEUROSCIENCE (2019)
Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients
Sonia Quintas et al.
PAIN MEDICINE (2019)
Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study
Marina de Tommaso et al.
EUROPEAN NEUROLOGY (2019)
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial
Udith A. Pijpers et al.
BRAIN (2019)
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study
C. Dominguez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
Pinar Yalinay Dikmen et al.
ACTA NEUROLOGICA BELGICA (2018)
The effects/injections of botulinum toxin in chronic migraine headache
M. Kara et al.
ACTA NEUROLOGICA SCANDINAVICA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal
A. P. Andreou et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
Andrew M. Blumenfeld et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study
William G. Ondo et al.
NEUROLOGY (2018)
Neurogenic inflammation and its role in migraine
Roshni Ramachandran
SEMINARS IN IMMUNOPATHOLOGY (2018)
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Michail Vikelis et al.
JOURNAL OF HEADACHE AND PAIN (2018)
CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature
Antoine Louveau et al.
NATURE NEUROSCIENCE (2018)
OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse
Edoardo Caronna et al.
FRONTIERS IN NEUROLOGY (2018)
Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial
Louise Ninett Carlsen et al.
CEPHALALGIA (2018)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
Zsolt Hepp et al.
CEPHALALGIA (2017)
Glycans Confer Specificity to the Recognition of Ganglioside Receptors by Botulinum Neurotoxin A
Christoffer Hamark et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
Jung-Ick Byun et al.
JOURNAL OF CLINICAL NEUROLOGY (2017)
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
Brendan Davies et al.
JOURNAL OF HEADACHE AND PAIN (2017)
The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
Manjit Matharu et al.
JOURNAL OF HEADACHE AND PAIN (2017)
OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study
Elif Ilgaz Aydinlar et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Marco Pirazzini et al.
PHARMACOLOGICAL REVIEWS (2017)
Long-term Treatment Benifits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
Simona Guerzoni et al.
FRONTIERS IN NEUROLOGY (2017)
Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe
Manjit Matharu et al.
CEPHALALGIA (2017)
Extracranial origin of headache
Rami Burstein et al.
CURRENT OPINION IN NEUROLOGY (2017)
Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study
Wichor M. Bramer et al.
SYSTEMATIC REVIEWS (2017)
Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches
Zdravko Lackovic et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
XiChun Zhang et al.
CEPHALALGIA (2016)
Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database
Zsolt Hepp et al.
CEPHALALGIA (2016)
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
Richard B. Lipton et al.
CEPHALALGIA (2016)
Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
I. Aicua-Rapun et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
Simona Guerzoni et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Onabotulinumtoxin-A treatment in Greek patients with chronic migraine
Michail Vikelis et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Medication-overuse headache: risk factors, pathophysiology and management
Hans-Christoph Diener et al.
NATURE REVIEWS NEUROLOGY (2016)
Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine
Bekir Enes Demiryurek et al.
NEUROLOGICAL SCIENCES (2016)
The use of onabotulinum toxin A (BotoxA®) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study
Marco Russo et al.
NEUROLOGICAL SCIENCES (2016)
Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A
Xiaqing Li et al.
PLOS ONE (2016)
Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgia
Chuanjie Wu et al.
SPRINGERPLUS (2016)
Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine
Kasra Maasumi et al.
HEADACHE (2015)
Modulation of intracranial meningeal nociceptor activity by cortical spreading depression: a reassessment
Jun Zhao et al.
JOURNAL OF NEUROPHYSIOLOGY (2015)
Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
Fayyaz Ahmed et al.
SPRINGERPLUS (2015)
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
Andrea Negro et al.
SPRINGERPLUS (2015)
OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
Maria Isabel Pedraza et al.
SPRINGERPLUS (2015)
Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
Eva Cernuda-Morollon et al.
CEPHALALGIA (2015)
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
Stephen D. Silberstein et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
S. K. Aurora et al.
ACTA NEUROLOGICA SCANDINAVICA (2014)
Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains
Rami Burstein et al.
CEPHALALGIA (2014)
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
H. -C. Diener et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Innervation of Rat and Human Dura Mater and Pericranial Tissues in the Parieto-Temporal Region by Meningeal Afferents
Markus Schueler et al.
HEADACHE (2014)
Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
John F. Rothrock et al.
HEADACHE (2014)
Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
Modar Khalil et al.
JOURNAL OF HEADACHE AND PAIN (2014)
Persistence of Botulinum Neurotoxin A Subtypes 1-5 in Primary Rat Spinal Cord Cells
Regina Clare Meyer Whitemarsh et al.
PLOS ONE (2014)
Trafficking of ThermoTRP Channels
Clotilde Ferrandiz-Huertas et al.
MEMBRANES (2014)
Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons
Jianghui Meng et al.
FASEB JOURNAL (2013)
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline
Stephen D. Silberstein et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain
Rodrigo Noseda et al.
PAIN (2013)
Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache
Markus Schueler et al.
PAIN (2013)
Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT/A)
Birgitte P. S. Jacky et al.
PLOS PATHOGENS (2013)
What sample sizes for reliability and validity studies in neurology?
Jeremy C. Hobart et al.
JOURNAL OF NEUROLOGY (2012)
Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A
Toshihiko Shimizu et al.
NEUROBIOLOGY OF DISEASE (2012)
Central Action of Peripherally Applied Botulinum Toxin Type A on Pain and Dural Protein Extravasation in Rat Model of Trigeminal Neuropathy
Boris Filipovic et al.
PLOS ONE (2012)
Botulinum Neurotoxin A Impairs Neurotransmission Following Retrograde Transynaptic Transport
Laura Restani et al.
TRAFFIC (2012)
Chemosensory Properties of the Trigeminal System
Felix Viana
ACS CHEMICAL NEUROSCIENCE (2011)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
Sheena K. Aurora et al.
HEADACHE (2011)
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
R. B. Lipton et al.
NEUROLOGY (2011)
BEHAVIORAL AND IMMUNOHISTOCHEMICAL EVIDENCE FOR CENTRAL ANTINOCICEPTIVE ACTIVITY OF BOTULINUM TOXIN A
I. Matak et al.
NEUROSCIENCE (2011)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program
Andrew Blumenfeld et al.
HEADACHE (2010)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick et al.
HEADACHE (2010)
Activation of Meningeal Nociceptors by Cortical Spreading Depression: Implications for Migraine with Aura
XiChun Zhang et al.
JOURNAL OF NEUROSCIENCE (2010)
The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane
Lucia Muraro et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential
Jianghui Meng et al.
JOURNAL OF NEUROSCIENCE (2009)
BOTULINUM TOXIN TYPE A (150 kDa) DECREASES EXAGGERATED NEUROTRANSMITTER RELEASE FROM TRIGEMINAL GANGLION NEURONS AND RELIEVES NEUROPATHY BEHAVIORS INDUCED BY INFRAORBITAL NERVE CONSTRICTION
Y. Kitamura et al.
NEUROSCIENCE (2009)
Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin
Parisa Gazerani et al.
PAIN (2009)
Mast cell degranulation activates a pain pathway underlying migraine headache
Dan Levy et al.
PAIN (2007)
Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A
Moshe Jakubowski et al.
PAIN (2006)
The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization
Parisa Gazerani et al.
PAIN (2006)
SV2 is the protein receptor for botulinum neurotoxin A
M Dong et al.
SCIENCE (2006)
Functional connectivity between trigeminal and occipital nerves revealed by occipital nerve blockade and nociceptive blink reflexes
V Busch et al.
CEPHALALGIA (2006)
Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy
PL Durham et al.
HEADACHE (2004)
Tbe development of cutaneous allodynia during a migraine attack - Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine
R Burstein et al.
BRAIN (2000)
Share Paper
